

# **EXHIBIT C**

# **HIGHLY CONFIDENTIAL**

Message

---

**From:** Venkat Krishnan [venkat@bionpharma.com]  
**Sent:** 2/15/2022 11:07:17 AM  
**To:** lavesh@bionpharma.com; gaurav@bionpharma.com  
**Subject:** FW: Follow on call

fyi

---

**From:** David Goodman <dgoodman@pharmascience.com>  
**Sent:** Tuesday, February 15, 2022 9:30 AM  
**To:** venkat@bionpharma.com  
**Subject:** FW: Follow on call

FYI.

David W. Goodman, Ph.D.  
Chief Executive Officer  
Pharmascience Inc.  
6111 Royalmount Avenue  
Montreal, Quebec. H4P 2T4  
tel. (514) 340-5071  
fax. (514) 342-3654  
email. [dgoodman@pharmascience.com](mailto:dgoodman@pharmascience.com)

---

**From:** Jeff Edwards <Jeff.Edwards@nqcapital.com>  
**Sent:** Tuesday, February 15, 2022 9:25 AM  
**To:** David Goodman <dgoodman@pharmascience.com>  
**Subject:** RE: Follow on call

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.  
CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

David-

Sorry for the tardiness in my reply. I'm speaking to Amit tomorrow and will call you afterwards.

Best,  
Jeff

Jeff Edwards  
Partner

4509 Creedmoor Rd, Suite 403 | Raleigh, NC 27612  
P: +1-919-261-5251  
M: +1-615-351-0717  
E-mail: [jeff.edwards@nqcapital.com](mailto:jeff.edwards@nqcapital.com)

CONFIDENTIALITY STATEMENT. This communication, including attachments, is intended solely for delivery to and authorized use by the addressee(s) identified above, and may contain privileged, confidential,

proprietary, trade secret and/or other information entitled to protection and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any use, disclosure, distribution, copying, printing, forwarding or saving of this communication, and/or any action or omission in reliance upon it, is strictly prohibited. If you have received this communication in error, please notify the sender immediately and delete this communication, including attachments, from your computer.

---

**From:** David Goodman <[dgoodman@pharmascience.com](mailto:dgoodman@pharmascience.com)>

**Sent:** Monday, February 7, 2022 1:50 PM

**To:** Jeff Edwards <[Jeff.Edwards@nqcapital.com](mailto:Jeff.Edwards@nqcapital.com)>

**Subject:** Follow on call

---

**External Sender:** This email originated from outside of the organization.

---

Dear Jeff,

I heard that Venkat spoke last week with Amit. Please let me know if you want to schedule another call. I could be free Wednesday morning , Thursday afternoon or Friday from 10:00-13:00.

Best Regards,

David W. Goodman, Ph.D.

Chief Executive Officer

Pharmascience Inc.

6111 Royalmount Avenue

Montreal, Quebec. H4P 2T4

tel. (514) 340-5071

fax. (514) 342-3654

email. [dgoodman@pharmascience.com](mailto:dgoodman@pharmascience.com)

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

**CERTIFICATE OF SERVICE**

I, Megan C. Haney, hereby certify that on June 2, 2023, a copy of Exhibits A-C to Defendant Bionpharma's Opposition to Plaintiff Azurity's Requests for a Protective Order and an Order Compelling Production was served upon the following counsel of record in the manner indicated below:

**VIA EMAIL**

Jack B. Blumenfeld  
Megan E. Dellinger  
Morris, Nichols, Arsht & Tunnell LLP  
1201 North Market Street  
P.O. Box 1347  
Wilmington, DE 19899  
jblumenfeld@morrisnichols.com  
mdellinger@morrisnichols.com

Wendy L. Devine  
Kristina M. Hanson  
Jody Karol  
Wilson Sonsini Goodrich & Rosati  
One Market Plaza, Spear Tower, Suite 3300  
San Francisco, CA 94105  
wdevine@wsgr.com  
thanson@wsgr.com  
jkarol@wsgr.com

Natalie J. Morgan  
Wilson Sonsini Goodrich & Rosati  
12235 El Camino Real, Suite 200  
San Diego, CA 94105  
nmorgan@wsgr.com

Granville C. Kaufman  
Ty W. Callahan  
Wilson Sonsini Goodrich & Rosati  
633 West Fifth Street, Suite 1550  
Los Angeles, CA 90071  
gkaufman@wsgr.com  
tcallahan@wsgr.com

Jeffrey C. Bank  
Alexander Poonai  
Wilson Sonsini Goodrich & Rosati  
1700 K Street, NW, Fifth Floor

Washington, DC 20006  
jbank@wsgr.com  
apoonai@wsgr.com

Azuritybionpharma505@wsgr.com

/s/ Megan C. Haney

Megan C. Haney (No. 5016)